ArticleDiagnostics (Basel, Switzerland)2022

Vedolizumab Attenuates Immune-Checkpoint-Therapy-Induced Infliximab-Refractory Colitis.

Ayaka Kaneoka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.